Hims & Hers Health, Inc.

NYSE:HIMS Stock Report

Market Cap: US$14.5b

Hims & Hers Health Management

Management criteria checks 3/4

Hims & Hers Health's CEO is Andrew Dudum, appointed in Jan 2017, has a tenure of 8.33 years. total yearly compensation is $24.61M, comprised of 2.3% salary and 97.7% bonuses, including company stock and options. directly owns 8.31% of the company’s shares, worth $1.20B. The average tenure of the management team and the board of directors is 2.2 years and 3.4 years respectively.

Key information

Andrew Dudum

Chief executive officer

US$24.6m

Total compensation

CEO salary percentage2.33%
CEO tenure8.3yrs
CEO ownership8.3%
Management average tenure2.2yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

Hims & Hers Health's (NYSE:HIMS) Performance Is Even Better Than Its Earnings Suggest

May 13
Hims & Hers Health's (NYSE:HIMS) Performance Is Even Better Than Its Earnings Suggest

Hims & Hers: Short-Lived Turbulence To Be Followed By New Phase Of Profitable Growth

May 12

After Leaping 89% Hims & Hers Health, Inc. (NYSE:HIMS) Shares Are Not Flying Under The Radar

May 08
After Leaping 89% Hims & Hers Health, Inc. (NYSE:HIMS) Shares Are Not Flying Under The Radar

Hims & Hers Health: GLP-1 Deals De-Risk The Story

Apr 29

Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy

Apr 23

With A 29% Price Drop For Hims & Hers Health, Inc. (NYSE:HIMS) You'll Still Get What You Pay For

Mar 24
With A 29% Price Drop For Hims & Hers Health, Inc. (NYSE:HIMS) You'll Still Get What You Pay For

Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There

Mar 20

Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety

Mar 03

Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity

Feb 25

Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)

Feb 19

Hims & Hers Health: Explosive Growth Potential Ahead

Feb 11

Market Participants Recognise Hims & Hers Health, Inc.'s (NYSE:HIMS) Revenues Pushing Shares 46% Higher

Feb 04
Market Participants Recognise Hims & Hers Health, Inc.'s (NYSE:HIMS) Revenues Pushing Shares 46% Higher

Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature

Jan 29

Hims & Hers Health: The Market Is Likely Wrong

Jan 19

Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns

Jan 09

Hims & Hers: Ready For Liftoff In 2025

Jan 02

Hims & Hers: FDA Ruling May Close Compounded GLP-1 Drug 'Loophole', It Was Fun While It Lasted

Dec 19

Hims & Hers: Look At What Matters Most

Dec 12

Hims & Hers: The Show Must Go On

Dec 05

Hims & Hers: Driving Growth In Wellness

Nov 29

Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 44% Share Price Surge

Nov 26
Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 44% Share Price Surge

Hims & Hers Health: The Amazon Curse Is Being Overstated

Nov 15

Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow

Nov 05

HIMS: GLP-1 Is Just The Beginning

Oct 17

Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward

Oct 03

Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce

Oct 01
Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce

Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now

Sep 24
author-image

Expanding Into Personalized Weight Management And AI Integration Spurs Market Leadership

Sep 05 Expansion into weight management and GLP-1 compounds addresses a massive potential market, suggesting diversification and possible revenue growth.

Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)

Aug 27

Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade

Aug 20

Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Aug 11
Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage

Aug 07

Hims & Hers: The Thesis Goes Far Beyond GLP-1

Jul 18

Hims & Hers: Buy The Dip To Catch The Next Rip

Jun 24

Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Jun 19
Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Hims & Hers: The Undervalued Gem Poised For Growth

Jun 18

Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable

Jun 10

CEO Compensation Analysis

How has Andrew Dudum's remuneration changed compared to Hims & Hers Health's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

US$164m

Dec 31 2024US$25mUS$573k

US$126m

Sep 30 2024n/an/a

US$101m

Jun 30 2024n/an/a

US$18m

Mar 31 2024n/an/a

-US$2m

Dec 31 2023US$14mUS$612k

-US$24m

Sep 30 2023n/an/a

-US$36m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$59m

Dec 31 2022US$11mUS$600k

-US$66m

Sep 30 2022n/an/a

-US$86m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$15mUS$574k

-US$108m

Sep 30 2021n/an/a

-US$82m

Jun 30 2021n/an/a

-US$72m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$27mUS$527k

-US$18m

Sep 30 2020n/an/a

-US$25m

Jun 30 2020n/an/a

-US$38m

Mar 31 2020n/an/a

-US$58m

Dec 31 2019US$254kUS$254k

-US$72m

Compensation vs Market: Andrew's total compensation ($USD24.61M) is above average for companies of similar size in the US market ($USD14.05M).

Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.

CEO

Andrew Dudum (35 yo)

8.3yrs

Tenure

US$24,609,077

Compensation

Mr. Andrew Dudum serves as Chairman of the Board and serves as Chief Executive Officer at Hims & Hers Health, Inc. since January 20, 2021. He Co-Founded Hims & Hers Health, Inc. in 2017. He is Co-founded H...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew Dudum
Co-Founder8.3yrsUS$24.61m8.31%
$ 1.2b
Oluyemi Okupe
Chief Financial Officer3.3yrsUS$8.20m0.053%
$ 7.7m
Soleil Boughton
Chief Legal Officer & Corporate Secretary4.3yrsUS$4.67m0.070%
$ 10.1m
Patrick Carroll
Chief Medical Officer & Director2.4yrsUS$203.36k0.094%
$ 13.6m
Mike Chi
Chief Commercial Officer1.1yrsUS$7.01m0.10%
$ 14.7m
Nader Kabbani
Chief Operations Officerno datano datano data
Irene Becklund
Senior VP5.9yrsUS$961.12k0.0023%
$ 328.5k
Mohamed ElShenawy
Chief Technology Officerno datano datano data
Khobi Brooklyn
Chief Communications Officer1.6yrsno datano data
Peter Stahl
Senior Vice President of Men’s Reproductive & Sexual Healthno datano datano data
Daniel Lieberman
Senior Vice President of Mental Health2.2yrsno datano data
Craig Primack
Senior Vice President of Weight Loss1.4yrsno datano data

2.2yrs

Average Tenure

41.5yo

Average Age

Experienced Management: HIMS's management team is considered experienced (2.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrew Dudum
Co-Founder4.3yrsUS$24.61m8.31%
$ 1.2b
Patrick Carroll
Chief Medical Officer & Director3.3yrsUS$203.36k0.094%
$ 13.6m
Peter Stahl
Senior Vice President of Men’s Reproductive & Sexual Health3.3yrsno datano data
Delos Cosgrove
Independent Director4.7yrsUS$199.36k0.024%
$ 3.5m
David Wells
Lead Independent Director4.7yrsUS$243.36k0.074%
$ 10.7m
Andrea Perez Garcia
Independent Director4.2yrsUS$214.36k0.032%
$ 4.7m
Lawrence Jenkins
Member of Medical Advisory Boardno datano datano data
Denise Asafu-Adjei
Member of Medical Advisory Board3.4yrsno datano data
Stanton Honig
Member of Medical Advisory Board3.4yrsno datano data
Stanley Althof
Member of Medical Advisory Boardless than a yearno datano data
Ranjith Ramasamy
Member of Medical Advisory Board3.4yrsno datano data
Bhavesh Shah
Member of Medical Advisory Board3.4yrsno datano data

3.4yrs

Average Tenure

53yo

Average Age

Experienced Board: HIMS's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/18 20:33
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hims & Hers Health, Inc. is covered by 20 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vikram KesavabhotlaBaird
Allen LutzBofA Global Research
Allen LutzBofA Global Research